WHO recommends Ervebo trial for Congo Ebola strain

Vaccine experts at the World Health Organization issued a recommendation on Friday for a full-scale human trial of the Ervebo vaccine in the Democratic Republic of Congo. The proposed study aims to determine whether the existing approved shot offers cross-protection against the Bundibugyo strain of the Ebola virus, which is currently spreading in the region.

Ervebo remains the only approved Ebola vaccine available, with established safety and efficacy data specifically for the Zaire strain. While the vaccine is proven to be effective against that variant, its applicability to the rarer Bundibugyo strain has not been confirmed in human trials. The World Health Organization’s recommendation seeks to address this gap in knowledge through rigorous clinical assessment.

Early data, including results from animal trials, have suggested that the Ervebo vaccine may provide protection against the Bundibugyo variant. However, these findings have not yet been validated in human subjects. The primary objective of the proposed trial is to confirm whether the cross-protection observed in preliminary studies translates to effective immunity in humans facing the current outbreak.

The Bundibugyo variant is considered a rarer strain of the Ebola virus compared to the Zaire strain, for which the vaccine is already authorised. Its current circulation in the Democratic Republic of Congo presents a distinct public health challenge. The World Health Organization’s intervention underscores the need to verify whether current immunisation tools can be utilised against this deadly and distinct variant.

The specific scale and timeline of the full-scale human trial have not been detailed in the available source material. The recommendation focuses on the necessity of establishing clinical efficacy data for the Bundibugyo strain, ensuring that public health responses in the Democratic Republic of Congo are grounded in confirmed scientific evidence rather than preliminary animal data.